MedTrace Logo

Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

NCT02329301 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2430

Last updated 2020-09-16

No results posted yet for this study

Summary

To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P. falciparum parasite prevalence, confirmed OPD malaria case incidence and cohort infection incidence in areas of high and low malaria transmission and in a program-relevant manner that will permit adoption and adaptation for wider-scale deployment.

Conditions

Interventions

DRUG

MDA with DHAp (Eurartesim)

Eurartesim is the brand name.

DRUG

Focal MDA with DHAp (Eurartesim)

Eurartesim is the brand name.

Sponsors & Collaborators

  • Ministry of Health, Zambia

    collaborator OTHER_GOV

  • Minister of Community Development, Mother and Child Health, Zambia

    collaborator OTHER

  • Tulane University

    collaborator OTHER

  • PATH

    lead OTHER

Principal Investigators

  • John M Miller, PhD · PATH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-06-30
Completion
2020-08-31

Countries

  • Zambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02329301 on ClinicalTrials.gov